The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Franco Locatelli
Co-Chair
Franco Locatelli is a full professor of pediatrics at the Sapienza University of Rome, IT, and head of the departments of Paediatric Haematology and Oncology and Cell and Gene Therapy, IRCCS Ospedale Bambino Gesù, Rome. Franco is a well-renowned expert of hematological malignant and non-malignant disorders of childhood. He leads the largest program for the treatment of childhood cancers in Italy and is the chairperson of the current diagnostic and treatment protocol for children with acute myeloid leukemia. He also chairs the working group on relapsed/refractory ALL in Italy. Franco has provided relevant contributions to the study of childhood myelodysplastic syndromes, thalassemia, innate immunity, immune reconstitution after transplantation, tumor immunology, induction of tolerance towards alloantigens, and antiviral cellular immunity in childhood malignancies. His current main fields of translational research are CAR (chimeric antigen receptor) T cells, T cells genetically modified with a suicide gene to accelerate immune recovery after allogeneic transplantation, and gene therapy/genome editing for thalassemia and sickle cell disease.
Filter by content: